Last reviewed · How we verify
3.5% ophthalmic lidocaine gel
At a glance
| Generic name | 3.5% ophthalmic lidocaine gel |
|---|---|
| Also known as | Akten |
| Sponsor | Miami VA Healthcare System |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study) (PHASE4)
- Topical Anesthesia and Intra-arterial Chemotherapy for Retinoblastoma (EARLY_PHASE1)
- Intraductal Meibomian Gland Probing Trial (PHASE4)
- Postoperative Subtenons Anesthesia for Postoperative Pain in Pediatric Strabismus Surgery (NA)
- Comparison of Patient Comfort After Two Anesthetic Protocols for Injections Into the Eye (NA)
- Patient Assessment of Topical Anesthetic Effectiveness for Intravitreal Injections (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 3.5% ophthalmic lidocaine gel CI brief — competitive landscape report
- 3.5% ophthalmic lidocaine gel updates RSS · CI watch RSS
- Miami VA Healthcare System portfolio CI